| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| F Villatte, T T Bachman, A S Hussein, R D Schmi. Acetylcholinesterase assay for rapid expression screening in liquid and solid media. BioTechniques. vol 30. issue 1. 2001-03-29. PMID:11196324. |
the synaptic enzyme acetylcholinesterase (ache), which is the target of many insecticides and potential warfare agents, is implied in alzheimer's disease and is a good potential candidate to be used in biosensors. |
2001-03-29 |
2023-08-12 |
Not clear |
| J J Sramek, N R Cutle. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer disease and associated disorders. vol 14. issue 4. 2001-02-08. PMID:11186600. |
red blood cell (rbc) acetylcholinesterase (ache) inhibition has been used as a peripheral surrogate marker for the activity of centrally acting ache inhibitors (acheis) in the treatment of alzheimer disease. |
2001-02-08 |
2023-08-12 |
human |
| J J Sramek, N R Cutle. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer disease and associated disorders. vol 14. issue 4. 2001-02-08. PMID:11186600. |
as a valid peripheral surrogate marker, rbc ache inhibition should reflect the central pharmacodynamic activity of the compound and should demonstrate a relation with cognitive or global improvement in patients with alzheimer disease. |
2001-02-08 |
2023-08-12 |
human |
| J J Sramek, N R Cutle. RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? Alzheimer disease and associated disorders. vol 14. issue 4. 2001-02-08. PMID:11186600. |
a study of rivastigmine in patients with alzheimer disease revealed that cerebrospinal fluid ache inhibition correlated well with cognitive performance, whereas peripheral inhibition did not. |
2001-02-08 |
2023-08-12 |
human |
| L J Scott, K L Go. Galantamine: a review of its use in Alzheimer's disease. Drugs. vol 60. issue 5. 2001-02-01. PMID:11129124. |
currently, acetylcholinesterase (ache) inhibitors are the most promising class of drugs for the treatment of alzheimer's disease (ad). |
2001-02-01 |
2023-08-12 |
Not clear |
| J Sáez-Valero, M S Barquero, A Marcos, C A McLean, D H Smal. Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 69. issue 5. 2000-11-21. PMID:11032625. |
previous studies have shown an abnormality in the glycosylation of acetylcholinesterase (ache) in the csf collected postmortem from patients with alzheimer's disease. |
2000-11-21 |
2023-08-12 |
Not clear |
| W Samuel, M Caligiuri, D Galasko, J Lacro, M Marini, F S McClure, K Warren, D V Jest. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. International journal of geriatric psychiatry. vol 15. issue 9. 2000-11-01. PMID:10984725. |
in several retrospective post-mortem studies, patients meeting clinical criteria for alzheimer's disease (ad) who gained the greatest cognitive benefit from treatment with an acetylcholinesterase (ache) inhibitor were found to have neocortical lewy bodies accompanying classical ad neuropathology. |
2000-11-01 |
2023-08-12 |
human |
| A S Alhomida, A A Al-Rajhi, M A Kamal, A A Al-Jafar. Kinetic analysis of the toxicological effect of tacrine (Cognex) on human retinal acetylcholinesterase activity. Toxicology. vol 147. issue 1. 2000-09-21. PMID:10837930. |
for the first time, kinetic parameters of the effect of tacrine, an anti-cholinesterase inhibitor of therapeutic potential in alzheimer's disease has been studied on human retinal acetyl-cholinesterase (ache). |
2000-09-21 |
2023-08-12 |
human |
| F I Braginskaia, O M Zorina, N P Pal'mina, V D Gaintseva, E B Burlakova, N D Selezneva, I V Kolykhalov, S I Gavrilov. [Certain biochemical blood markers in the process of cholinergic therapy in Alzheimer's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 100. issue 6. 2000-08-23. PMID:10900685. |
acetylcholinesterase (ache) activity and parameters of the system of regulation of lipid peroxidation (lpo) were estimated in blood of patients with alzheimer's disease (ad) during therapy with amiridine and gliatiline. |
2000-08-23 |
2023-08-12 |
Not clear |
| M A Kamal, N H Greig, A S Alhomida, A A Al-Jafar. Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. Biochemical pharmacology. vol 60. issue 4. 2000-08-21. PMID:10874131. |
characterization of the kinetic parameters of tolserine, a novel acetylcholinesterase (ache) inhibitor of potential in the therapy of alzheimer's disease, to inhibit purified human erythrocyte ache was undertaken for the first time. |
2000-08-21 |
2023-08-12 |
human |
| M Shapira, A Grant, M Korner, H Sore. Genomic and transcriptional characterization of the human ACHE locus: complex involvement with acquired and inherited diseases. The Israel Medical Association journal : IMAJ. vol 2. issue 6. 2000-08-01. PMID:10897240. |
abnormal levels of the acetylcholinesterase enzyme or aberrations involving the long arm of chromosome 7, harboring the ache gene at 7q22, occur in various diseases such as alzheimer's, parkinson's, and leukemias. |
2000-08-01 |
2023-08-12 |
human |
| G Jeyarasasingam, M Yeluashvili, M Qui. Tacrine, a reversible acetylcholinesterase inhibitor, induces myopathy. Neuroreport. vol 11. issue 6. 2000-07-17. PMID:10817586. |
tacrine, an acetylcholinesterase (ache) inhibitor that has been used in the treatment of alzheimer's disease, increases available acetylcholine (ach) levels in the synaptic cleft thereby enhancing the activity of cholinergic pathways. |
2000-07-17 |
2023-08-12 |
rat |
| W F Li. Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats. Neurotoxicology and teratology. vol 22. issue 3. 2000-07-12. PMID:10840182. |
the acetylcholinesterase (ache) inhibitors physostigmine (phy), tacrine (tha), and heptylphysostigmine (hep) have been evaluated as potential therapeutics for treatment of alzheimer's disease (ad) and as prophylactics against organophosphate (op) poisoning. |
2000-07-12 |
2023-08-12 |
rat |
| M Recanatini, A Cavalli, F Belluti, L Piazzi, A Rampa, A Bisi, S Gobbi, P Valenti, V Andrisano, M Bartolini, V Cavrin. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. Journal of medicinal chemistry. vol 43. issue 10. 2000-06-29. PMID:10821713. |
in this study, we attempted to derive a comprehensive sar picture for the class of acetylcholinesterase (ache) inhibitors related to tacrine, a drug currently in use for the treatment of the alzheimer's disease. |
2000-06-29 |
2023-08-12 |
Not clear |
| A Golbraikh, P Bernard, J R Chrétie. Validation of protein-based alignment in 3D quantitative structure-activity relationships with CoMFA models. European journal of medicinal chemistry. vol 35. issue 1. 2000-06-19. PMID:10733609. |
3d quantitative structure-activity relationship (3d qsar) models have been derived for a series of n-benzylpiperidine derivatives which are potent acetylcholinesterase (ache) inhibitors interesting for alzheimer's disease. |
2000-06-19 |
2023-08-12 |
Not clear |
| A Rampa, A Bisi, F Belluti, S Gobbi, P Valenti, V Andrisano, V Cavrini, A Cavalli, M Recanatin. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives. Bioorganic & medicinal chemistry. vol 8. issue 3. 2000-06-01. PMID:10732965. |
this finding seems particularly important in the context of alzheimer's disease research in the light of recent observations showing that peripheral ache inhibitors might decrease the aggregating effects of the enzyme on the beta-amyloid peptide (betaa). |
2000-06-01 |
2023-08-12 |
Not clear |
| J Kaur, M Q Zhan. Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors. Current medicinal chemistry. vol 7. issue 3. 2000-03-30. PMID:10637365. |
acetylcholinesterase (ache) inhibitors are an important class of medicinal agents useful for the treatment of alzheimer s disease, glaucoma, myasthenia gravis and for the recovery of neuromuscular block in surgery. |
2000-03-30 |
2023-08-12 |
Not clear |
| H Sugimoto, Y Yamanishi, Y Iimura, Y Kawakam. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Current medicinal chemistry. vol 7. issue 3. 2000-03-30. PMID:10637367. |
a wide range of evidence shows that acetylcholinesterase (ache) inhibitors can interfere with the progression of alzheimer's disease (ad). |
2000-03-30 |
2023-08-12 |
Not clear |
| H Sugimoto, Y Yamanishi, Y Iimura, Y Kawakam. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Current medicinal chemistry. vol 7. issue 3. 2000-03-30. PMID:10637367. |
the earliest known ache inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of alzheimer's patients. |
2000-03-30 |
2023-08-12 |
Not clear |
| Y Ishihara, G Goto, M Miyamot. Central selective acetylcholinesterase inhibitor with neurotrophic activity: structure-activity relationships of TAK-147 and related compounds. Current medicinal chemistry. vol 7. issue 3. 2000-03-30. PMID:10637368. |
therefore, tak-147 is expected not only to ameliorate the clinical symptoms in alzheimer s disease via ache inhibition but to prevent or slow the progression of the disease via its neurotrophic action. |
2000-03-30 |
2023-08-12 |
Not clear |